As a preventive measure, some countries have decided to suspend vaccination with the British vaccine after reports of adverse reactions.
It’s a real slaughter! After Iceland, Italy, Austria, Norway, Denmark and the Netherlands, it is the turn of Germany and France to stop vaccination with the Anglo-Swedish vaccine. The health authorities of the various countries react following cases of thrombosis (formation of blood clots) which are sometimes fatal. On the side of the Swedish-British pharmaceutical group and the University of Oxford, the discourse is not the same: “There is very reassuring evidence that there is no increase in the blood clot phenomenon here in the UK, where most doses in Europe have been administered so far.“Professor Andrew Pollard, director of the Oxford Vaccine Group, which developed the vaccine with AstraZeneca, told the BBC on Monday (March 15th).
Germany believes further reviews are needed
Germany is preventively suspending the use of this vaccine. The German Ministry of Health announced this on Monday and refers to a current recommendation from the Paul Ehrlich Institute regarding necessary additional examinations.
According to the German media, the Bild “The Paul Ehrlich Institute emphasizes that people who have already received the Covid-19 vaccine from AstraZeneca and who experience various side effects within four days such as severe headaches or occasional skin bleeding should immediately consult a doctor”. However, the German daily tempers by saying that the cases are rare and that in Germany, only seven cases have been recorded so far.
France suspends the use of AstraZeneca for 24 hours
“The European authority will issue an opinion tomorrow afternoon on the use of this vaccine”, specified the President of the Republic during the Franco-Spanish summit organized in Montauban. The Head of State also indicated that this decision responds to a logic of conformity with European policy. “As a precaution, vaccination with AstraZeneca is therefore suspended. Hoping to resume it quickly, if the opinion of the European Medicines Agency allows it “.
